Baseline characteristics of the 17 patients with HIV infection who received gene-modified CD4+ and CD8+ T cells
| Characteristic . | Value . |
|---|---|
| Previous therapy, no. (%) of patients | |
| Gene-modified CD8+ T cells | 7 (41) |
| Interleukin 2 plus gene-modified CD8+ T cells | 4 (24) |
| Unmodified CD8+ T cells | 6 (35) |
| Median CD4 count, (range) | 415 (169-1867) |
| HIV RNA | |
| Median log10 copies/mL (range) | 2.37 (1.37-5.25) |
| No. (%) of patients with <50 copies/mL | 6 (35) |
| Antiretroviral therapy, no. of patients | |
| NRTIs only | 3 |
| NRTIs and PI | 14 |
| Characteristic . | Value . |
|---|---|
| Previous therapy, no. (%) of patients | |
| Gene-modified CD8+ T cells | 7 (41) |
| Interleukin 2 plus gene-modified CD8+ T cells | 4 (24) |
| Unmodified CD8+ T cells | 6 (35) |
| Median CD4 count, (range) | 415 (169-1867) |
| HIV RNA | |
| Median log10 copies/mL (range) | 2.37 (1.37-5.25) |
| No. (%) of patients with <50 copies/mL | 6 (35) |
| Antiretroviral therapy, no. of patients | |
| NRTIs only | 3 |
| NRTIs and PI | 14 |
NRTIs indicates nucleoside reverse transcriptase inhibitors; and PI, protease inhibitor.